Market Closed - Xetra 16:43:44 25/06/2024 BST Pre-market 06:32:01
8.825 EUR +2.74% Intraday chart for Evotec SE 8.795 -0.34%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday MT
Evotec Gets $39 Million Contract With U.S. Defense Department DJ
Evotec Unit Bags Contract to Develop Accelerated Antibody Manufacturing Platform for US Government MT
Evotec Subsidiary Gets Multi-Year US Defense Department Contract for Up to $39 Million MT
Evotec receives additional contract from US Department of Defense DP
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15 DP
Evotec In Talks With Advisers Amid Takeover Worries MT
European shares advance on tech, real estate boost; Swiss stocks shine RE
Takeover fantasy drives Evotec recovery DP
Frankfurt shares close: Dax recovers DP
Evotec on the decline - expert fears further profit warning DP
Evotec benefits modestly from research payment DP
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb CI
EVOTEC : RBC remains its Buy rating ZD
Evotec Partners With French Institutions, Company to Research Obesity MT
Evotec Joins Collaboration to Identify New Therapies for Obesity, Metabolic Diseases MT
Evotec, Inserm, Lille Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases CI
Evotec Extends Drug Discovery Collaboration With CHDI Foundation for Huntington's Disease MT
Evotec, CHDI Foundation Extend 20-year Partnership for Huntington's Disease Treatments MT
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington?s Disease CI
EVOTEC : Deutsche Bank maintains a Buy rating ZD
Evotec Shares Rise Following Gene Therapy Exit, Q1 Results MT
EVOTEC : RBC gives a Buy rating ZD
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.825 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.58%
Consensus
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE
  5. Evotec Names First Chief People Officer